$SPRO
Spero Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024127016 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $13.47M
YoY Change -47.12%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.198M
YoY Change -8.97%
% of Gross Profit
Research & Development $26.86M
YoY Change 63.87%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $32.06M
YoY Change 16.98%
Operating Profit -$18.59M
YoY Change 861.38%
Interest Expense $1.182M
YoY Change 24.42%
% of Operating Profit
Other Income/Expense, Net $1.156M
YoY Change 22.98%
Pretax Income -$17.44M
YoY Change 1661.31%
Income Tax -$290.0K
% Of Pretax Income
Net Earnings -$17.10M
YoY Change 434.38%
Net Earnings / Revenue -126.96%
Basic Earnings Per Share -$0.32
Diluted Earnings Per Share -$0.32
COMMON SHARES
Basic Shares Outstanding 54.52M 54.05M
Diluted Shares Outstanding 54.12M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $76.29M
YoY Change -18.67%
Cash & Equivalents $76.29M
Short-Term Investments
Other Short-Term Assets $2.055M
YoY Change -61.94%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $131.6M
YoY Change 28.77%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $153.0K
YoY Change -64.75%
Total Long-Term Assets $3.534M
YoY Change -27.57%
TOTAL ASSETS
Total Short-Term Assets $131.6M
Total Long-Term Assets $3.534M
Total Assets $135.2M
YoY Change 26.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.090M
YoY Change 452.13%
Accrued Expenses $17.07M
YoY Change 105.63%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $49.10M
YoY Change 92.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $20.56M
YoY Change -26.32%
Total Long-Term Liabilities $20.56M
YoY Change -26.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $49.10M
Total Long-Term Liabilities $20.56M
Total Liabilities $69.65M
YoY Change 30.45%
SHAREHOLDERS EQUITY
Retained Earnings -$438.8M
YoY Change -0.79%
Common Stock $504.3M
YoY Change 1.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $65.51M
YoY Change
Total Liabilities & Shareholders Equity $135.2M
YoY Change 26.2%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$17.10M
YoY Change 434.38%
Depreciation, Depletion And Amortization $0.00
YoY Change -100.0%
Cash From Operating Activities $12.76M
YoY Change -19.83%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities 12.76M
Cash From Investing Activities
Cash From Financing Activities 0.000
Net Change In Cash 12.76M
YoY Change -20.92%
FREE CASH FLOW
Cash From Operating Activities $12.76M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001701108
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#LicenseMember
CY2023Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#LicenseMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#LicenseMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#LicenseMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38266
dei Entity Registrant Name
EntityRegistrantName
SPERO THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4590683
dei Entity Address Address Line1
EntityAddressAddressLine1
675 Massachusetts Avenue,
dei Entity Address Address Line2
EntityAddressAddressLine2
14th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
242-1600
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
SPRO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54518165
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76290000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76333000
CY2024Q3 spro Collaboration Receivable Related Parties Current
CollaborationReceivableRelatedPartiesCurrent
50586000
CY2023Q4 spro Collaboration Receivable Related Parties Current
CollaborationReceivableRelatedPartiesCurrent
49152000
CY2024Q3 us-gaap Other Receivables
OtherReceivables
2696000
CY2023Q4 us-gaap Other Receivables
OtherReceivables
1545000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2055000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4178000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
131627000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
131208000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3381000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4155000
CY2024Q3 spro Collaboration Receivable Related Parties Non Current
CollaborationReceivableRelatedPartiesNonCurrent
0
CY2023Q4 spro Collaboration Receivable Related Parties Non Current
CollaborationReceivableRelatedPartiesNonCurrent
46590000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
153000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
435000
CY2024Q3 us-gaap Assets
Assets
135161000
CY2023Q4 us-gaap Assets
Assets
182390000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6090000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1378000
CY2024Q3 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
15328000
CY2023Q4 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6557000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1739000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1718000
CY2024Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
97000
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
387000
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
788000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2132000
CY2024Q3 spro Deferred Revenue Current Related Party
DeferredRevenueCurrentRelatedParty
25054000
CY2023Q4 spro Deferred Revenue Current Related Party
DeferredRevenueCurrentRelatedParty
24981000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
49096000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
37153000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2883000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3825000
CY2024Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
11850000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10825000
CY2024Q3 spro Deferred Revenue Non Current Related Partys
DeferredRevenueNonCurrentRelatedPartys
5812000
CY2023Q4 spro Deferred Revenue Non Current Related Partys
DeferredRevenueNonCurrentRelatedPartys
23606000
CY2024Q3 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
13000
CY2023Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
87000
CY2024Q3 us-gaap Liabilities
Liabilities
69654000
CY2023Q4 us-gaap Liabilities
Liabilities
75496000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54314415
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54314415
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52999680
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52999680
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
54000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
53000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
504203000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
497913000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-438750000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-391072000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
65507000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
106894000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
135161000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
182390000
CY2024Q3 spro Grant Revenue
GrantRevenue
5650000
CY2023Q3 spro Grant Revenue
GrantRevenue
2091000
spro Grant Revenue
GrantRevenue
14893000
spro Grant Revenue
GrantRevenue
5349000
CY2024Q3 spro Collaboration Revenue Related Party
CollaborationRevenueRelatedParty
7754000
CY2023Q3 spro Collaboration Revenue Related Party
CollaborationRevenueRelatedParty
23164000
spro Collaboration Revenue Related Party
CollaborationRevenueRelatedParty
17721000
spro Collaboration Revenue Related Party
CollaborationRevenueRelatedParty
24200000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
65000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
218000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
319000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
710000
CY2024Q3 us-gaap Revenues
Revenues
13469000
CY2023Q3 us-gaap Revenues
Revenues
25473000
us-gaap Revenues
Revenues
32933000
us-gaap Revenues
Revenues
30259000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26864000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16393000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
67921000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34883000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5198000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5708000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16648000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19121000
CY2024Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
5306000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
5306000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
32062000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
27407000
us-gaap Operating Expenses
OperatingExpenses
84569000
us-gaap Operating Expenses
OperatingExpenses
59310000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18593000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1934000
us-gaap Operating Income Loss
OperatingIncomeLoss
-51636000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29051000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1182000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
950000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3707000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2894000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-26000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-39000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-17000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1156000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
940000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3668000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2877000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Interest Expense Interest Income Income Taxes Extraordinary Items Noncontrolling Interests Net
IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet
-17437000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Interest Expense Interest Income Income Taxes Extraordinary Items Noncontrolling Interests Net
IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet
-994000
us-gaap Income Loss From Continuing Operations Before Interest Expense Interest Income Income Taxes Extraordinary Items Noncontrolling Interests Net
IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet
-47968000
us-gaap Income Loss From Continuing Operations Before Interest Expense Interest Income Income Taxes Extraordinary Items Noncontrolling Interests Net
IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet
-26174000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-290000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2211000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-290000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2211000
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-17147000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-3205000
us-gaap Profit Loss
ProfitLoss
-47678000
us-gaap Profit Loss
ProfitLoss
-28385000
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.89
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.89
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54124862
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54124862
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52710280
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52710280
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53869824
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53869824
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52603709
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52603709
us-gaap Profit Loss
ProfitLoss
-47678000
us-gaap Profit Loss
ProfitLoss
-28385000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
329000
spro Non Cash Lease Cost
NonCashLeaseCost
775000
spro Non Cash Lease Cost
NonCashLeaseCost
720000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
5306000
us-gaap Share Based Compensation
ShareBasedCompensation
6290000
us-gaap Share Based Compensation
ShareBasedCompensation
5935000
spro Increase Decrease In Collaboration Receivable Related Party Current And Noncurrent
IncreaseDecreaseInCollaborationReceivableRelatedPartyCurrentAndNoncurrent
-45156000
spro Increase Decrease In Collaboration Receivable Related Party Current And Noncurrent
IncreaseDecreaseInCollaborationReceivableRelatedPartyCurrentAndNoncurrent
0
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1151000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1905000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2123000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2029000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-282000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4712000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
486000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
8771000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2410000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-319000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-709000
spro Increase Decrease In Deferred Revenue Related Party
IncreaseDecreaseInDeferredRevenueRelatedParty
-17721000
spro Increase Decrease In Deferred Revenue Related Party
IncreaseDecreaseInDeferredRevenueRelatedParty
5800000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-74000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-35000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-921000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-816000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-290000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
2211000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15502000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
220000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
220000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-43000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15282000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
76333000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
109107000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
76290000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
93825000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
80500000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2154000
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-17147000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
65507000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
106894000
us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
1000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6290000
us-gaap Profit Loss
ProfitLoss
-47678000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
65507000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
54782000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
220000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1908000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-3205000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
53705000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
75934000
us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
1000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
220000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5935000
us-gaap Profit Loss
ProfitLoss
-28385000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
53705000
CY2024Q4 spro Workforce Reduction Percent
WorkforceReductionPercent
0.39
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-17100000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-3200000
us-gaap Profit Loss
ProfitLoss
-47700000
us-gaap Profit Loss
ProfitLoss
-28400000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-438800000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the accrual for clinical trial costs and other research and development expenses and the valuation of share-based awards. There may be changes to those estimates in future periods. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and of Significant Suppliers</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains most of its cash and cash equivalents at one accredited financial institution. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and December 31, 2023, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> off-balance sheet risks, including but not limited, to foreign exchange contracts, option contracts, or other hedging arrangements.</span></span></p>
us-gaap Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk
ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
As of September 30, 2024 and December 31, 2023, the Company had no off-balance sheet risks, including but not limited, to foreign exchange contracts, option contracts, or other hedging arrangements.
CY2024Q3 us-gaap Fair Value Disclosure Offbalance Sheet Risks Amount Asset
FairValueDisclosureOffbalanceSheetRisksAmountAsset
0
CY2023Q4 us-gaap Fair Value Disclosure Offbalance Sheet Risks Amount Asset
FairValueDisclosureOffbalanceSheetRisksAmountAsset
0
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2024Q3 spro Percentage Of Tax Benefit Recognized
PercentageOfTaxBenefitRecognized
0.50
CY2024Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
700000
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
700000
spro Fair Value Liabilities Of Level2 To Level1 Transfers Amount
FairValueLiabilitiesOfLevel2ToLevel1TransfersAmount
0
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3279000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3339000
CY2024Q3 spro Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
11240000
CY2023Q4 spro Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
2274000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
619000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
708000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
190000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
236000
CY2024Q3 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
15328000
CY2023Q4 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6557000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2865594
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.89
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M3D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
35604
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.52
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
44535
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
13.36
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2856663
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.73
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y9M
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2856663
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
10.73
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y9M
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2615440
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.54
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P4Y7M6D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0
spro Unrecognized Compensation Expense
UnrecognizedCompensationExpense
2100000
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2154000
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1908000
us-gaap Share Based Compensation
ShareBasedCompensation
6290000
us-gaap Share Based Compensation
ShareBasedCompensation
5935000
CY2024Q3 spro Potential Amount Of Uncommitted Funding
PotentialAmountOfUncommittedFunding
12700000
CY2024Q3 spro Milestone Payment Upon Submission Of A New Drug Application
MilestonePaymentUponSubmissionOfANewDrugApplication
225000000
CY2024Q3 spro Sales Milestone Events
SalesMilestoneEvents
1000000000
CY2023Q4 spro Total Milestone
TotalMilestone
95000000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17147000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3205000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47678000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28385000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54124862
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54124862
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52710280
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52710280
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53869824
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53869824
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52603709
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52603709
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.89
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.89
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10347004
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7747834
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10347004
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7747834
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-127016-index-headers.html Edgar Link pending
0000950170-24-127016-index.html Edgar Link pending
0000950170-24-127016.txt Edgar Link pending
0000950170-24-127016-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img175229707_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
spro-20240930.htm Edgar Link pending
spro-20240930.xsd Edgar Link pending
spro-ex10_1.htm Edgar Link pending
spro-ex10_2.htm Edgar Link pending
spro-ex10_3.htm Edgar Link pending
spro-ex10_4.htm Edgar Link pending
spro-ex31_1.htm Edgar Link pending
spro-ex31_2.htm Edgar Link pending
spro-ex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
spro-20240930_htm.xml Edgar Link completed